LY-CoV555

Identification

Name
LY-CoV555
Accession Number
DB15718
Description

LY-CoV555, also known as LY3819253, is a synthetic monoclonal antibody (mAb) derived from one of the first blood samples taken in the United States from a patient who recovered from COVID-19.1,2 LY-CoV555 is a neutralizing IgG1 mAb directed against the SARS-CoV-2 spike (S) protein, which is described to block viral entry into human cells.1,2

AbCellera initially discovered LY-CoV555 in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), and subsequently further developed in collaboration with Eli Lilly and Company. It is set to enter phase three clinical trials.2,3

Type
Biotech
Groups
Investigational
Synonyms
Not Available
External IDs
  • LY-3819253
  • LY-CoV555
  • LY3819253

Pharmacology

Indication
Not Available
Contraindications & Blackbox Warnings
Learn about our commercial Contraindications & Blackbox Warnings data.
Learn More
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Learn about our commercial Adverse Effects data.
Learn More
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Categories

Drug Categories
Classification
Not classified

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
  1. Eli Lilly: Initial LY-CoV555 statement [Link]
  2. Eli Lilly: LY-CoV555 phase three statement [Link]
  3. NIH: LYCoV555 phase three statement [Link]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3RecruitingPreventionNovel Coronavirus Infectious Disease (COVID-19)1
3RecruitingTreatmentNovel Coronavirus Infectious Disease (COVID-19)1
2RecruitingTreatmentNovel Coronavirus Infectious Disease (COVID-19)1
2, 3RecruitingTreatmentInfections, Coronavirus / Novel Coronavirus Infectious Disease (COVID-19)1
1CompletedBasic ScienceNovel Coronavirus Infectious Disease (COVID-19)1
1Not Yet RecruitingBasic ScienceHealthy Volunteers1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created on August 06, 2020 11:33 / Updated on August 09, 2020 01:20

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Covid drug repurpose